salicylic acid and Cicatrization studies

Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).

Cicatrization: The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.

Research Excerpts

Excerpt	Relevance	Reference
"Many clinicians have used glycolic acid (GA) peels for facial acne, scarring, and hyperpigmentation, mainly in lighter skin types."	7.75	Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. ( Garg, VK; Sarkar, R; Sinha, S, 2009)
"Many clinicians have used glycolic acid (GA) peels for facial acne, scarring, and hyperpigmentation, mainly in lighter skin types."	3.75	Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. ( Garg, VK; Sarkar, R; Sinha, S, 2009)
"Multiple approaches are used to treat acne scars, but some are expensive, ineffective, and cause complications."	3.11	Combination treatment with 30% salicylic acid and fractional CO ( Chen, J; Chen, JY; Chen, YM; Liu, L; Pu, YH; Shao, XY; Zhang, LZ; Zhang, YJ, 2022)
"When untreated, scarring alopecia develops."	3.01	EROSIVE PUSTULAR DERMATOSIS OF THE SCALP (EPDS) - A CASE SERIES AND SHORT REVIEW. ( Wollina, U, 2023)
"When a cicatricial alopecia is suspected, scalp biopsy is recommended."	2.82	Treatment of Alopecia in Children. ( Gold, M; Goldust, M; Grabbe, S; Mishra, P; Patil, A; Rudnicka, L; Sinclair, R, 2022)
"At Month 12, hyperplastic scars at these donor sites of cicatricial skin were assessed through Vancouver Scar Assessment Table, scar itch assessment and scar proliferation rate."	2.78	[Clinical study of repairing donor site of thickness from cicatricial skin with auto-scalp grafting]. ( Cai, JD; Cai, JH; Chai, JK; Li, DJ; Shen, CA; Tuo, XY; Wang, SJ; Zhang, L; Zhu, H, 2013)
"We evaluate a new technique of treating scalp lacerations, the hair apposition technique (HAT)."	2.70	A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study). ( Hock, MO; Lim, SH; Ooi, SB; Saw, SM, 2002)
"The incidence of inflammation, suppuration and hypertrophic scarring was recorded, along with the timing of spontaneous suture disappearance."	2.69	Outcomes of irradiated polyglactin 910 Vicryl Rapide fast-absorbing suture in oral and scalp wounds. ( Aderriotis, D; Sàndor, GK, 1999)
"Twelve patients with post-burn contracture were treated using artificial dermis combined with thin split-skin grafting during the period January 1994 to April 1996."	2.68	Reconstruction of burn deformity using artificial dermis combined with thin split-skin grafting. ( Negishi, N; Nozaki, M; Sasaki, K; Soejima, K; Takeuchi, M, 1997)
"Analyzing other scarring diseases (lichen planopilaris, fibrotic kidney disease and scleroderma) may help to clarify the mechanism of scarring in CCCA."	2.66	A proposed mechanism for central centrifugal cicatricial alopecia. ( Alexander, T; Beamer, V; McMichael, A; Subash, J, 2020)
"In addition, the scar width was 60 to 76 percent larger in the Dexon group 3 months postoperatively."	2.66	Absorbable versus nonabsorbable sutures to prevent postoperative stretching of wound area. ( Nordström, RE; Nordström, RM, 1986)
"diffuse and scarring vs."	2.53	Diagnosis and management of hair loss in children. ( Castelo-Soccio, L, 2016)
"With regards to non-scarring alopecia, there were eight horizontal and eight vertical section studies."	2.53	Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. ( Du, X; Fan, W; Li, Z; Song, C; Tang, S; Xu, W; Zhou, X, 2016)
"Folliculitis keloidalis is a cicatricial alopecia with a mixed inflammatory infiltrate."	2.52	Primary scarring alopecias. ( Ioannides, D; Rigopoulos, D; Stamatios, G, 2015)
"Hair loss is commonly seen in autoimmune diseases."	2.50	Hair loss in autoimmune systemic diseases. ( Cozzani, E; Parodi, A, 2014)
"Keloid scarring is more prevalent in individuals of African, Asian, and Hispanic descent."	2.50	Follicular and scarring disorders in skin of color: presentation and management. ( Kundu, RV; Madu, P, 2014)
"The relationship between nonscarring scalp alopecia in women and iron deficiency continues to be a subject of debate."	2.46	Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle. ( Donovan, JC; Hordinsky, MK; St Pierre, SA; Vercellotti, GM, 2010)
"As is well known, scars are the indelible ransom of any surgical procedure and the major obstacle confronting patients and surgeons from an aesthetic standpoint."	2.44	Minimal scars for scalp surgery. ( Frechet, P, 2007)
"A requirement for developing successful treatments for postacne scarring is a greater understanding of its pathogenesis, variability among afflicted individuals, and the inflammatory mediators and immunology of the scarring process."	2.44	The management of postacne scarring. ( Baron, JA; Goodman, GJ, 2007)
"Cicatricial or scarring alopecia represents permanent destruction of the hair follicle, histopathologically showing a decreased number of follicular units leaving streamers of fibrosis or hyalinization of surrounding collagen."	2.44	Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. ( Griffin, T; Severs, GA; Werner-Wasik, M, 2008)
"Although single-scar techniques have been published and are used by approximately half of all surgeons, this approach is not as common as one might suspect."	2.42	Intricacies of the single-scar technique for donor harvesting in hair transplantation surgery. ( Brandy, DA, 2004)
"Unsightly donor scars and fibrosis are still not only with us, but are possibly even more pervasive than ever."	2.41	Hair transplantation: management of donor area. ( Seery, GE, 2002)
"Primary and secondary scarring alopecia are differentiated: While the former is due to preferential destruction of the follicle, the latter results from events outside the follicle, which eventually impinge upon and eradicate the follicle."	2.40	[Cicatricial alopecias: diagnosis and therapy]. ( Trüeb, RM, 1997)
"The development of malignancy in burn scars is a well known entity."	2.40	Sarcoma developing in a burn scar: case report and review of the literature. ( Apaydin, EI; Can, Z; Kuzu, I; Riza, A; Yilmaz, S, 1998)
"A 23-year-old man with frontal hair loss underwent follicular unit strip surgery."	1.91	A Scalp Scar-Reducing Procedure for the Hair Transplant Donor Area Using a Columnar Trichophytic Suture: A Case Report. ( Kim, J; Kim, T; Park, G; Park, J, 2023)
"Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body."	1.91	Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023)
"None of the cases had diagnosis of type 2 diabetes mellitus, but 17."	1.91	Central centrifugal cicatricial alopecia in males. ( Ayoade, KO; Jackson, TK; Ogunleye, T; Seykora, JT; Sow, Y; Taylor, SC, 2023)
"To evaluate the safety and efficacy of FUE when combined with an expanded scalp flap for facial organ reconstruction."	1.91	Hair follicle extraction combined with an expanded scalp flap for facial organ reconstruction. ( Fan, Z; Gan, Y; Hu, Z; Le, D; Liu, B; Mao, X; Miao, Y; Qu, Q; Sun, P; Zhang, J, 2023)
"However, this approach leaves long scars that in numerous patients, it can cause extensive surrounding alopecia and sensory skin deficits."	1.72	A new aesthetic pretrichial approach for upper third-facial fractures and pathologies: The "Crown incision". ( De Riu, G; Massarelli, O; Vaira, LA, 2022)
" In this study, we present an alternative technique to reconstruct the aesthetic units using an expanded scalp flap combined with laser hair removal."	1.72	Expanded scalp flap combined with laser hair removal to reconstruct facial defects around the hairline. ( Chu, F; Ding, J; Liu, S; Ma, X; Tang, Y; Yu, Z, 2022)
" This article introduces an approach to reconstruct total facial injuries with a prefabricated expanded thoracic flap combined with an expanded scalp flap (called combined flaps), which not only solves the limitations of blood supply and expanded volume but also reduces patchwork scars."	1.62	Prefabricated Expanded Flap Combined With Expanded Scalp Flap for Total Face Resurfacing. ( Char, S; Liu, Y; Shi, Y; Sun, H; Tan, X; Wang, X; Yang, C; Yao, J; Yao, P, 2021)
"Burn scar and alopecia on hair-bearing areas can severely affect the social life of patients."	1.62	Hair Transplantation in Burn Scar Alopecia After Combined Non-Ablative Fractional Laser and Microfat Graft Treatment. ( Agaoglu, E; Agaoglu, G; Erol, O; Karademir, S; Özer, F, 2021)
"All patients had no obvious scar at the donor sites."	1.56	Clinical outcomes and technical tips for eyebrow restoration using single-follicular-unit hair transplantation: A case series review. ( Jiang, W; Wang, B; Wang, M, 2020)
"All cases resembled deep-reaching scars with almost complete loss of all adnexal structures."	1.56	Aplasia cutis congenita of the scalp: Histopathologic features and clinicopathologic correlation in a case series. ( Bösmüller, H; Gassenmaier, M; Metzler, G, 2020)
"Surgical scar length is a common concern among patients undergoing Mohs micrographic surgery (MMS)."	1.51	A Predictive Model for Primary Closure Lengths in Mohs Surgery Based on Skin Cancer Type, Dimensions, and Location. ( Blechman, AB; Russell, MA; Theroux, ZA, 2019)
"Patients with androgenetic alopecia (AGA) and alopecia areata (AA), and scarring alopecia, in particular frontal fibrosing alopecia (FFA) were recruited and imaged from July 2016 to July 2017."	1.51	Feature characterization of scarring and non-scarring types of alopecia by multiphoton microscopy. ( Atanaskova Mesinkovska, N; Balu, M; Koenig, K; Lentsch, G; Lin, J; Saknite, I; Tromberg, BJ; Valdebran, M; Williams, JN, 2019)
"Only burn scars caused post-ulceration periods of more than 24 months (7/19)."	1.51	A review of 31 cases of Marjolin's ulcer on scalp: Is it necessary to preventively remove the scar? ( Cen, Y; Chen, Z; Deng, K; Gao, Y; Lin, Y; Liu, R; Xiao, H; Xu, X, 2019)
"To characterize scar formation and hair growth in nonhealing ulcers after transplantation."	1.51	Distinct Patterns of Hair Graft Survival After Transplantation Into 2 Nonhealing Ulcers: Is Location Everything? ( Alam, M; Cooley, J; Izeta, A; Jimenez, F; Martínez-Martín, MS; Paus, R; Plotczyk, M, 2019)
"Of note, patchy primary scarring alopecia (SA) needs to be clearly distinguished from AA as SA can leave permanent hair loss."	1.51	Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient. ( Fukuyama, M; Ohyama, M, 2019)
"Indication included burn scar (n=14) and congenital nevus (n=5)."	1.51	Choosing the right rectangular expander and maximising the benefits from expanded tissue. ( Aksam, E; Durgun, M, 2019)
"In follicular scars, EVG demonstrated central attenuation and loss of the elastic network with peripheral clumping and recoil of elastic fibers."	1.48	Elastic Staining in Differentiating Between Follicular Streamers and Follicular Scars in Horizontal Scalp Biopsy Sections. ( Gerami, P; Guitart, J; Tan, T; Yazdan, P, 2018)
"Low grade glioma (LGG) is a very common primary brain neoplasm with a very good prognosis and the median survival of patients is approximately 8 years."	1.48	Cutaneous Metastases of the Glioma. ( Chang, H; Ding, Y; Li, B; Lin, Y; Wang, P; Wang, Q, 2018)
"The pattern of hair loss was more likely to be unifocal-ragged border in CCCA and DLE, multifocal-interconnected in LPP and FD, and multifocal-separated in DC."	1.48	Primary scarring alopecia: A retrospective study of 89 patients in Taiwan. ( Cheng, AY; Chu, CB; Hsu, CK; Lee, CN; Lee, JY; Liu, CH; Su, HJ; Yang, CC, 2018)
"One patient had a hypertrophic scar and no hair transfers to the recipient areas were observed."	1.48	Scalp as a donor site in children: Is it really the best option? ( Adams, S; Rode, H; van Niekerk, G, 2018)
"Sarcoidosis is a granulomatous condition that has a highly variable presentation."	1.48	Scalp Sarcoidosis Presenting as Cicatricial Alopecia. ( Cook, C; Demaree, E; Powers, J; Prohaska, J, 2018)
"In stage 2, scarring tissues were excised and the expanded hair-bearing flaps were advanced to the defect."	1.48	Staged reconstructive treatment for extensive irregular cicatricial alopecia after burn. ( Cheng, H; Jia, M; Li, J; Shen, H; Sun, Z; Tang, L; Tang, S; Wu, X; Zhang, J; Zhou, J, 2018)
"One patient had hair loss of the upper cutaneous lip."	1.46	Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. ( Camilleri, MJ; Chaudhry, HM; Tolkachjov, SN; Torgerson, RR, 2017)
"The seaming scar between the deltopectoral flap and scalp flap in the temple region formed the new hairline."	1.46	Reconstruction of Large Postburn Facial-Scalp Scars by Expanded Pedicled Deltopectoral Flap and Random Scalp Flap: Technique Improvements to Enlarge the Reconstructive Territory. ( Li, W; Li, Y; Liu, C; Lu, K; Ma, X; Peng, P; Song, B; Su, Y; Xia, W; Yi, C, 2017)
"Cutaneous sarcoidosis is not an uncommon disorder, and the skin can be the sole manifestation in about 10% of patients."	1.46	Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis. ( Didona, D; Donati, M; Donati, P; Panetta, C; Paolino, G, 2017)
"To investigate the feasibility and therapeutic effect of frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi."	1.46	[Frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi]. ( Chen, C; Li, B; Li, W; Sun, Z, 2017)
"Several reported cases have described scarring alopecia of the scalp, which is the area of skin most commonly affected by sarcoidosis."	1.43	Sarcoidosis presenting as non-scarring non-scalp alopecia. ( Dan, L; Relic, J, 2016)
"Neither scar nor alopecia was found in the skin-harvesting region, and hairs grew well."	1.43	[Scalp surface skin grafts in reconstruction of external auditory meatus in congenital aural atresia]. ( Huang, QH; Jiang, HL; Liang, MJ; Liu, Y; Si, Y; Xu, G; Zhang, ZG, 2016)
"The donor-site scar was larvaceous and the function was good."	1.43	Free perforating branch flap for primary repairing the huge soft-tissue defects on the scalp and face. ( Chu, YJ; Sun, JW; Wang, HY; Wang, K; Wang, MG; Wei, XP; Yu, G, 2016)
"Therefore, scar widening and hair loss after craniotomy, which sometimes occurs in this disease, are serious problems for patients."	1.42	Zigzag skin incision effectively camouflages the scar and alopecia for moyamoya disease: technical note. ( Kato, A; Kubota, H; Sanada, Y; Yabuuchi, T; Yoshioka, H, 2015)
"To investigate the therapeutic effect of scalp expanded flap combined with JPL hair removal for large area scar on forehead."	1.42	[Scalp expanded flap combined with IPL hair removal for large area scar on forehead]. ( Hongwei, Y; Hua, L; Hui, G; Li, C; Li, Z; Peng, W; Xia, Y, 2015)
"Subjective scar evaluation of the donor sites was performed using the Patient Scar Assessment Scale (PASA)."	1.40	Comparison of scalp and abdomen as split-thickness skin graft donor sites for aural stenosis repair. ( Du, Q; Zhang, T, 2014)
"Occipital scars from donor strip harvesting during hair transplantation are an important cosmetic concern."	1.40	Measuring occipital scalp laxity before donor strip harvesting in hair transplantation. ( Chang, CH; Chang, SL; Gold, MH; Hu, S; Huang, YL; Lee, MC, 2014)
"Defect diameters and resultant scar lengths were recorded."	1.39	Versatility of the pinwheel flap to reconstruct circular defects in the temporal and scalp region. ( Eroglu, L; Simsek, T, 2013)
"Alopecia is the fifth most common dermatologic diagnosis in African-American patients."	1.39	Prospective histologic examinations in patients who practice traumatic hairstyling. ( Mehregan, DM; Uhlenhake, EE, 2013)
"The causes of scar resulting to hair loss were burns, operation, and trauma."	1.39	Hair follicle transplantation on scar tissue. ( Hoon Koh, S; Jung, S; Oh, SJ, 2013)
"This leaves a visible scar that may not be cosmetically acceptable."	1.39	Subcutaneoscopic excision of external angular dermoid cyst in children without conspicuous scarring. ( Acharya, H; Agarwal, P; Agrawal, V; Sekhon, V; Sharma, D, 2013)
"The pathogenesis of scarring alopecia in African American women remains poorly understood."	1.39	Transversely sectioned biopsies in the diagnosis of end-stage traction alopecia. ( Donovan, JC; Mirmirani, P, 2013)
"FFA is an increasingly common form of scarring hair loss, but the origin remains unknown."	1.39	Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. ( Bazakas, A; Ladizinski, B; Olsen, EA; Selim, MA, 2013)
"Another common problem is the scar enlargement."	1.38	Long-term results in scalp tissue expansion in children. ( Calibre, C; Duquennoy-Martinot, V; Herbaux, B; Maillet-Declerck, M, 2012)
"The results showed minimal scarring and hair regrowth in what could have been large defects requiring complex reconstruction."	1.36	The use of the flexible scalpel for minimally invasive and minimally scarring surgery: a case series of four patients with large scalp tumors. ( Firoz, BF; Friedman, PM; Goldberg, LH; Katz, T; Kimyai-Asadi, A, 2010)
"All had frontotemporal recession with scarring."	1.35	Frontal fibrosing alopecia: clinical presentations and prognosis. ( Messenger, AG; Tan, KT, 2009)
"In a specialized hair loss clinic, a group of patients was identified with focal or complete hair loss at the scalp periphery, with a normal scalp surface."	1.35	Cicatricial marginal alopecia: is it all traction? ( Goldberg, LJ, 2009)
"Tinea capitis is the most common dermatophyte infection in children."	1.35	Tinea capitis mimicking cicatricial alopecia: what host and dermatophyte factors lead to this unusual clinical presentation? ( Chamlin, S; Frieden, IJ; Mirmirani, P; Price, VH; Willey, A, 2009)
"When the hemangiomas were stratified into "large" and "small" hemangiomas, the median percentage reduction in the areas were 84."	1.35	Purse-string closure of hemangiomas: early results of a follow-up study. ( Rohde, CH; Wu, JK, 2009)
"Cicatricial or scarring alopecia results in the destruction of hair follicles and is a significant cosmetic concern in African-American women."	1.35	Scarring alopecia: clinical and pathologic study of 54 African-American women. ( Borovicka, JH; Mehregan, DR; Prince, C; Thomas, L, 2009)
"Although non-scarring diffuse hair loss has been frequently observed in systemic lupus erythematosus (SLE) patients, the pattern of hair loss with regard to its frequency in SLE has been rarely studied."	1.34	Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia. ( Kim, SJ; Kim, SY; Lee, JB; Lee, JW; Lee, SC; Lee, SS; Won, YH; Yoon, HJ; Yun, SJ, 2007)
"These lesions resolved gradually with scar formation."	1.33	A case of lupus erythematosus profundus with unusual manifestations. ( Alpsoy, E; Bacanli, A; Ciftcioglu, MA; Uzun, S, 2005)
"The postburn scars were removed, and the wounds were covered by superficial cervical artery island skin flaps."	1.33	[The use of superficial cervical artery island skin flaps in the repair of the maxillofacial and cervical scar]. ( Chen, SJ; Han, WJ; Wang, B; Wang, DL; Wang, YM; Wei, ZR, 2005)
"Aplasia cutis congenita is a special condition, with local vascular abnormalities: local flaps are prohibited."	1.33	[Scalp surgery in children: principles and therapeutic aspects]. ( Buis, J; Delbecque, M; Franchi, G; Picard, A; Sergent, B; Vazquez, MP, 2005)
"Female pattern hair loss (FPHL) is a common hair disorder of the central scalp."	1.33	Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. ( Olsen, EA, 2005)
"Sclerodermatous skin changes and scarring alopecia are described in up to 20% of patients."	1.33	Large, nonhealing scalp ulcer associated with scarring alopecia and sclerodermatous change in a patient with porphyria cutanea tarda. ( Bergamo, BM; Inglese, MJ, 2005)
"None of the other patients had any scarring; they were completely healed by day 15."	1.33	The scalp is an advantageous donor site for thin-skin grafts: a report on 945 harvested samples. ( Chaouat, M; Mimoun, M; Picovski, D; Serroussi, D; Smarrito, S, 2006)
"Most patients were men treated for androgenic alopecia."	1.32	Algorithm of hair restoration surgery in children. ( Kolasiñski, J; Kolenda, M, 2003)
"Neck scar contractures were released in all cases, and good results were obtained not only functionally but also aesthetically."	1.32	Clinical and basic research on occipito-cervico-dorsal flaps: including a study of the anatomical territories of dorsal trunk vessels. ( Gao, JH; Hyakusoku, H; Murakami, M; Ogawa, R, 2004)
"Wide unsightly scars, stretch-atrophied hypesthetic, poorly vascularized tissues and distorted hair patterns are still commonly seen and appear to be largely refractory to remedial surgery."	1.31	Surgical anatomy of the scalp. ( Seery, GE, 2002)
"The authors report a case of aplasia cutis congenita of the scalp associated with bilateral coronal synostosis."	1.31	Surgical treatment of aplasia cutis congenita of the scalp associated with bilateral coronal synostosis. ( Arai, H; Ichida, M; Inoue, M; Komuro, Y; Miyajima, M; Sato, K; Seno, H; Yanai, A, 2002)
"Hair loss from the flap was rare."	1.31	New treatment of a visible linear scar in the scalp: multiple hair-bearing flap technique. ( Sawada, Y; Urushidate, S; Watanabe, Y; Yamashita, K; Yokoi, K; Yotsuyanagi, T, 2002)
"Accurate data for the area of scar excision and the expanded cervicofacial flap were obtained by using this measuring system in a young patient with scar contracture of the face."	1.31	Assessment of facial tissue expansion with three-dimensional digitizer scanning. ( Ji, Y; Lineaweaver, WC; Schwartz, J; Stile, F; Zhang, F, 2002)
"Although alopecia areata is a common problem among children, many misdiagnoses for this condition can happen."	1.31	Striae distensae-like lesions. A cause of scarring alopecia among children. ( Al-Nuaimy, AA; Al-Waiz, MM; Sharquie, KE, 2002)
"To better define the pathogenesis of acne keloidalis (AK)."	1.31	Acne keloidalis is a form of primary scarring alopecia. ( Homoky, C; Pratt, L; Sau, P; Sperling, LC, 2000)
"The conspicuousness of such a scar results from its linear continuity and hairlessness."	1.31	Immediate hair transplantation into a newly closed wound to conceal the final scar on the hair-bearing skin. ( Barutçu, A; Seyhan, A; Yoleri, L, 2000)
"Unsightly scalp scars, refractory to surgical revision, can pose a difficult therapeutic problem."	1.31	Micropigmentation as an adjuvant in cosmetic surgery of the scalp. ( Traquina, AC, 2001)
"The biggest dimension of repaired baldness was 340 cm2, one expander exposed and one failed in expanding after operation and be corrected immediately."	1.31	[Treating cicatricial baldness with scalp expanding and hair autografting]. ( Li, AL; Yan, YZ; Yu, MS, 2001)
"The quality of the scar was excellent in the majority of cases."	1.31	Face lifts with hidden scars: the vertical U incision. ( Brady, JA; Chiou, P; Marchac, D, 2002)
"The visible linear scar of the scalp is a cosmetically serious complication of a scalp incision in scalp surgery, forehead lift, and craniofacial surgery, especially on the temporal scalp."	1.30	Prevention and treatment of wide scar and alopecia in the scalp: wedge excision and double relaxation suture. ( Burm, JS; Oh, SJ, 1999)
"POEMS syndrome is a rare condition with cutaneous manifestations commonly including angiomas, hypertrichosis, hyperpigmentation, and thickening of the skin."	1.30	POEMS syndrome: cicatricial alopecia as an unusual cutaneous manifestation associated with an underlying plasmacytoma. ( Feller, AC; Meigel, W; Mensing, H; Ramsauer, J; Stemm, AV; Weichenthal, M, 1999)
"Anterior scalp scars may be improved by punch excision and micrografting."	1.30	Hair repair surgery. Corrective measures for improvement of older large-graft procedures and scalp scars. ( Swinehart, JM, 1999)
"Although hidden, the scar placement permits full correction of redundant neck skin."	1.30	Hiding the posterior scar in rhytidectomy: the omega incision. ( Little, JW, 1999)
"Malignant fibrous histiocytoma (MFH) which is usually originated from muscles and deep fascia and rarely from the subcutaneous tissue is the most common soft tissue sarcoma; and it frequently invades the extremities."	1.30	Malignant fibrous histiocytoma developing in a burn scar. ( Baş, L; Kabukçuoğlu, F; Ozcan, H; Sanus, Z; Turgut, G; Uğurlu, K, 1999)
"45 cases with baldness following burn from 1988 to 1998 were reported."	1.30	[The clinical application of scalp expansion in the repair of cicatricial baldness in children]. ( Gao, Z; Liu, Y; Yang, J, 1999)
"Temporary hair loss is well accepted as a possible result of psoriatic plaques."	1.29	[Scarring psoriatic alopecia]. ( Bonsmann, G; Kretzschmar, L; Luger, TA; Metze, D; Schwarz, T, 1995)
"Dermoids are congenital subcutaneous cysts, which gradually flatten and scar over a number of years."	1.28	Congenital inclusion dermoid cysts of the scalp. ( Darley, C; Dawber, RP; Sinclair, RD, 1992)
"Radiation-induced meningiomas have a characteristic biological behaviour, so that their recognition is important as regards follow-up."	1.28	A scalp lesion over an extracerebral mass: a sign of a radiation-induced meningioma. ( Climent, V; García Santos, JM, 1992)
"In 1885 Brocq described a type of scarring alopecia he called pseudopelade (PPB), whose character as a separate disease entity has been denied in recent decades."	1.28	[The Brocq pseudopelade--a disease picture or disease entity]. ( Bergner, T; Braun-Falco, O; Heilgemeir, GP, 1989)
"In six patients, burn scar of the scalp caused by direct exposure to fire in their infancy was a pathogenesis underlying the development of the malignancy, and the time interval was estimated to be an average of 53 years."	1.28	[Surgical management of squamous-cell carcinomas arising in burn scar of the scalp]. ( Kikuchi, K; Konno, A; Kowada, M; Mineura, K; Sakamoto, T, 1989)
"The metaplastic synovial cyst (synovial metaplasia of the skin) is a recently described intradermal cyst lined by a membrane that resembles hyperplastic synovium."	1.27	Metaplastic synovial cyst after partial excision of nevus sebaceus. ( Sexton, FM; Stern, DR, 1988)
"Facial burn scars are difficult to conceal and often preclude an aesthetic rehabilitation of the patient."	1.27	The temporal island scalp flap for management of facial burn scars. ( Argenta, LC; Friedman, RJ; Marks, MW; Thornton, JW, 1988)
"41 cases with scarring alopecia seen from 1979 to 1983 were analyzed and differentiated."	1.27	Pseudopelade of Brocq. ( Bergner, T; Braun-Falco, O; Imai, S; Schmoeckel, C; Steger, O, 1986)
"A 17-year-old boy had a large, scarred area of alopecia from a thermal burn."	1.26	Scalp reduction for alopecia. ( Roenigk, HH; Schultz, BC, 1979)

Research

Studies (356)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP

Timeframe	Studies, this research(%)	All Research%
pre-1990	67 (18.82)	18.7374
1990's	50 (14.04)	18.2507
2000's	81 (22.75)	29.6817
2010's	108 (30.34)	24.3611
2020's	50 (14.04)	2.80

Authors	Studies
Zhang, YJ	1
Chen, YM	1
Shao, XY	1
Liu, L	2
Pu, YH	1
Zhang, LZ	1
Chen, JY	1
Chen, J	2
Han, Q	1
Zeng, J	1
Liu, Y	6
Yin, J	1
Sun, P	2
Wu, Y	1
Garg, VK	1
Sinha, S	1
Sarkar, R	1
COLIN, R	1
DOSSA, J	1
POUS, JG	1
Danielson, JR	1
Walter, RJ	1
Samrao, A	1
Lyon, L	1
Mirmirani, P	4
Massarelli, O	1
Vaira, LA	1
De Riu, G	1
Mishra, P	1
Patil, A	1
Sinclair, R	5
Gold, M	1
Rudnicka, L	2
Grabbe, S	1
Goldust, M	1
Jamerson, TA	1
Conover Talbot, C	1
Dina, Y	1
Kwatra, SG	1
Garza, LA	1
Aguh, C	2
Cuadrado, ML	1
González-García, N	1
Porta-Etessam, J	1
de Andrade Lima, MMD	1
Benez, M	1
Gamonal, SBL	1
Melo, DF	1
Tortelly, VD	1
Frattini, S	1
de Andrade Lima, EV	1
Liu, S	1
Tang, Y	1
Ding, J	1
Chu, F	1
Yu, Z	1
Ma, X	2
Venter, TH	1
Parker, GR	1
Rogers, AD	1
Clapham, LE	1
Mende, K	1
Park, JH	3
Ho, YH	1
Manonukul, K	1
Ali, S	1
Collins, M	1
Taylor, SC	2
Kelley, K	1
Stratton, E	1
Senna, M	1
Miteva, M	2
Nadji, M	1
Billero, V	1
LaSenna, C	1
Nattkemper, L	1
Romanelli, P	1
Sons, JS	3
Chateau, AV	3
Douglas, A	1
Romisher, A	1
Cohen, A	1
Zaya, R	1
Wang, J	5
Suriano, J	1
Zachian, R	1
Nikbakht, N	1
Wollina, U	1
Park, G	1
Kim, J	3
Kim, T	1
Park, J	1
Pearce, J	1
Al-Wahab, Y	1
Brent, G	1
Natkunarajah, J	1
Larrondo, J	1
McMichael, AJ	3
Sode, T	1
Ogwumike, E	1
Hosler, GA	1
Khalid, I	1
Riopelle, AM	1
Jeong, D	1
Boyd, AY	1
Schanbacher, CF	1
Pitch, MA	1
Sperling, LC	5
Liu, J	1
Wang, Y	1
Jackson, TK	1
Sow, Y	1
Ayoade, KO	1
Seykora, JT	1
Ogunleye, T	1
Heymann, WR	1
Le, D	1
Gan, Y	1
Mao, X	1
Qu, Q	1
Fan, Z	1
Liu, B	1
Zhang, J	2
Hu, Z	1
Miao, Y	1
Kuka Epstein, G	1
Epstein, J	1
Tan, TL	1
Doytcheva, K	1
Guitart, J	2
Gerami, P	2
Yazdan, P	2
Ramot, Y	1
Bertolini, M	1
Boboljova, M	1
Uchida, Y	1
Paus, R	2
Jiang, W	2
Wang, M	2
Wang, B	3
Gassenmaier, M	1
Bösmüller, H	1
Metzler, G	1
Fernandez-Flores, A	1
Maguire, M	1
Drumm, C	1
Woods, G	1
Mullally, W	1
Redmond, M	1
Grogan, L	1
O'Kane, M	1
Sorger, C	1
Mentzel, J	1
Simon, JC	1
Treudler, R	1
Trindade de Carvalho, L	1
Meah, N	1
Wall, D	1
Sullivan, JV	1
Dziewulski, P	1
Shelley, OP	1
El Shabrawi-Caelen, L	1
McMichael, A	6
Eginli, A	2
Cooley, J	2
Seyhan, T	1
Kapi, E	1
Mohmand, MH	1
Ahmad, M	2
Sun, H	1
Yao, P	1
Shi, Y	1
Char, S	1
Wang, X	1
Yao, J	1
Yang, C	1
Tan, X	2
Chen, L	1
Jia, L	1
Olshinka, A	1
Ad-El, D	1
Kalish, E	1
Shay, T	1
Yaacobi, DS	1
Lorei, NC	1
Sullivan, JF	1
Lennon, RP	1
Milder, EA	1
Roman, JW	1
Agaoglu, G	1
Özer, F	1
Karademir, S	1
Agaoglu, E	1
Erol, O	1
Olsen, EA	4
Harries, M	1
Tosti, A	6
Bergfeld, W	2
Blume-Peytavi, U	1
Callender, V	1
Chasapi, V	1
Correia, O	1
Cotsarelis, G	2
Dhurat, R	1
Dlova, N	1
Doche, I	1
Enechukwu, N	1
Grimalt, R	1
Itami, S	1
Hordinsky, M	1
Khobzei, K	1
Lee, WS	2
Malakar, S	1
Messenger, A	1
Ovcharenko, Y	1
Papanikou, S	1
Pinto, GM	1
Piraccini, BM	1
Pirmez, R	1
Reygagne, P	1
Roberts, J	1
Saceda-Corralo, D	1
Shapiro, J	1
Silyuk, T	1
Soares, RO	1
Souissi, A	1
Vogt, A	1
Washenik, K	1
Zlotogorski, A	1
Canfield, D	1
Vano-Galvan, S	1
Berenguer, B	1
García, T	1
Lorca-García, C	1
San-Basilio, M	1
Tsao, SB	1
Jong, LR	1
Su, YC	1
Kuo, YR	1
Dothard, E	1
Bagayoko, CW	1
Huang, K	1
Daniel, A	1
Lim, JH	1
Siow, WS	1
Tan, LS	1
Elston, DM	1
Tolkachjov, SN	1
Chaudhry, HM	1
Camilleri, MJ	1
Torgerson, RR	1
Li, Y	1
Li, W	2
Liu, C	1
Peng, P	1
Song, B	1
Xia, W	2
Yi, C	2
Lu, K	2
Su, Y	1
Tan, T	1
Vazquez-Herrera, NE	1
Eber, AE	1
Martinez-Velasco, MA	1
Perper, M	1
Cervantes, J	1
Verne, SH	1
Magno, RJ	1
Nouri, K	1
Harb, JN	1
Owens, AL	1
Potter, KM	1
Montuno, M	1
De Jesus, RO	1
Konda, S	1
Khouri, KS	1
Cardoso, E	1
Khouri, RK	1
Chang, H	1
Ding, Y	1
Wang, P	1
Wang, Q	1
Lin, Y	2
Li, B	2
Katoulis, AC	1
Diamanti, K	1
Sgouros, D	1
Liakou, AI	1
Bozi, E	1
Avgerinou, G	1
Panayiotides, I	1
Rigopoulos, D	2
Su, HJ	1
Cheng, AY	1
Liu, CH	1
Chu, CB	1
Lee, CN	1
Hsu, CK	1
Lee, JY	1
Yang, CC	1
Sundberg, JP	1
Hordinsky, MK	2
Lenzy, YM	2
Christiano, AM	1
McGregor, T	1
Stenn, KS	1
Sivamani, RK	1
Pratt, CH	1
King, LE	1
Gomes, RC	1
Guirro, ECO	1
Gonçalves, AC	1
Farina Junior, JA	1
Murta Junior, LO	1
Guirro, RRJ	1
van Niekerk, G	1
Adams, S	1
Rode, H	1
Zimmerman, B	1
Ivars, M	1
Cordoro, KM	1
Subash, J	1
Alexander, T	1
Beamer, V	1
Theroux, ZA	1
Blechman, AB	1
Russell, MA	1
Paolino, G	1
Panetta, C	1
Didona, D	1
Donati, M	1
Donati, P	1
Chen, C	1
Sun, Z	2
Arif, T	1
Adil, M	1
Suhail Amin, S	1
Alam, M	2
Lin, J	1
Saknite, I	1
Valdebran, M	1
Balu, M	1
Lentsch, G	1
Williams, JN	1
Koenig, K	1
Tromberg, BJ	1
Atanaskova Mesinkovska, N	1
You, SH	2
Kim, NR	1
Prohaska, J	1
Demaree, E	1
Powers, J	1
Cook, C	1
Xiao, H	1
Deng, K	1
Liu, R	1
Chen, Z	1
Gao, Y	1
Cen, Y	1
Xu, X	2
Tang, S	2
Wu, X	1
Cheng, H	1
Shen, H	1
Tang, L	1
Zhou, J	1
Jia, M	1
Li, J	1
Plotczyk, M	1
Martínez-Martín, MS	1
Izeta, A	1
Jimenez, F	1
Wada, N	1
Uchi, H	1
Furue, M	1
Malki, L	1
Sarig, O	1
Romano, MT	1
Méchin, MC	1
Peled, A	1
Pavlovsky, M	1
Warshauer, E	1
Samuelov, L	1
Uwakwe, L	1
Briskin, V	1
Mohamad, J	1
Gat, A	1
Isakov, O	1
Rabinowitz, T	1
Shomron, N	1
Adir, N	1
Simon, M	1
Dlova, NC	1
Betz, RC	1
Sprecher, E	1
Garcia-Robledo, JE	1
Aragón, CC	1
Nieto-Aristizábal, I	1
Vásquez, S	1
Montoya, C	1
Tobón, GJ	1
Fukuyama, M	1
Ohyama, M	1
Kaya İslamoğlu, ZG	1
Uysal, E	1
Durgun, M	1
Aksam, E	1
Hou, Z	1
Lee, PK	1
Yoo, H	1
Moh, J	1
Park, JU	1
Divine, J	1
Rudnick, EW	1
Lien, M	1
Croley, JAA	1
Hirshburg, JM	1
Wagner, RF	1
Nirmal, B	1
George, R	1
Eftekhari, H	1
Azimi, SZ	1
Rafiei, R	1
Darjani, A	1
Alizadeh, N	1
Rafiei, E	1
Ghadarjani, R	1
Gharaei Nejad, K	1
Simsek, T	1
Eroglu, L	1
Horenstein, MG	1
Bacheler, CJ	1
Uhlenhake, EE	1
Mehregan, DM	1
László, FG	1
Rogers, NE	3
Kluger, N	1
Cavelier-Balloy, B	1
Assouly, P	1
Filbrandt, R	1
Rufaut, N	1
Jones, L	1
Cascio, A	1
Torina, A	1
Valenzise, M	1
Blanda, V	1
Camarda, N	1
Bombaci, S	1
Iaria, C	1
De Luca, F	1
Wasniewska, M	1
Hundeshagen, G	2
Assadov, KF	1
Podmelle, F	1
Jung, S	2
Oh, SJ	3
Hoon Koh, S	1
Shen, CA	1
Chai, JK	1
Zhang, L	1
Li, DJ	1
Tuo, XY	1
Cai, JH	1
Wang, SJ	1
Zhu, H	1
Cai, JD	1
Agrawal, V	1
Acharya, H	1
Agarwal, P	1
Sekhon, V	1
Sharma, D	1
Buchwach, KA	1
Donovan, JC	2
Du, Q	1
Zhang, T	1
Loh, CC	1
Su, JC	1
Daniel, BS	1
Venugopal, SS	1
Rhodes, LM	1
Intong, LR	1
Law, MG	1
Murrell, DF	1
Moh, JS	1
Lee, SY	1
Lampeter, W	1
Delacerda, AB	1
Chandler, RG	1
Wells, MJ	1
Vindhya, PL	1
Parodi, A	1
Cozzani, E	1
Torres, F	2
Huang, X	1
Liu, K	1
Gu, B	1
Li, Q	1
Esposito, C	1
Escolino, M	1
Paternoster, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE[NCT04300296]	Phase 2	111 participants (Actual)	Interventional	2020-07-27	Completed
Evaluation of the Postoperative Effect of Expanded Pedicled Deltopectoral Flap to Repair the Facial-Cervical Scars[NCT03735641]		50 participants (Anticipated)	Observational	2018-10-01	Enrolling by invitation
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)[NCT03016715]	Phase 2	8 participants (Anticipated)	Interventional	2016-05-31	Recruiting
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)[NCT02960997]	Phase 2	8 participants (Actual)	Interventional	2016-05-31	Completed
Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris[NCT05535517]		15 participants (Anticipated)	Observational	2022-08-13	Recruiting
Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients[NCT03044782]		34 participants (Actual)	Observational [Patient Registry]	2016-08-31	Completed
A Method of Calculating the Shortest Incision for Internal Fixation of Zygomatic Arch Fracture: Sideburns Mini Incision[NCT05381337]		80 participants (Actual)	Interventional	2021-01-01	Completed
Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma[NCT05263141]		80 participants (Anticipated)	Interventional	2022-03-01	Recruiting
Triamcinolone Acetonide as an Adjuvant to Pre-emptive Scalp Infiltration for Relief of Post-craniotomy Pain in Adults[NCT06069804]	Phase 4	130 participants (Anticipated)	Interventional	2023-09-25	Recruiting
Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278]		60 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain: A Prospective Clinical and Dosimetric Study of Primary and Metastatic Brain Tumour Patients[NCT03543020]		25 participants (Actual)	Observational	2017-07-17	Terminated (stopped due to inadequate patient number)
Easy Way of Choosing Rectangular Expander and Getting Maximum Benefit From Expanded Tissue[NCT03544697]		19 participants (Actual)	Observational	2013-01-31	Completed
A Pilot Study Comparing Cutaneous Scarring When Scalpel Versus Cautery is Used to Make Skin Incisions[NCT00803140]		4 participants (Actual)	Interventional	2008-11-30	Terminated (stopped due to Slow accrual of subject enrollment.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model. (NCT04300296)
Timeframe: Baseline up to week 16

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

Intervention	percentage of participants (Median)
AIN457 300 mg Q4W - TP 1 - CLP Cohort	44.0
Placebo - TP 1 - CLP Cohort	58.2
AIN457 300 mg Q4W - TP 1 - MLP Cohort	37.5
Placebo - TP 1 - MLP Cohort	23.1
AIN457 300 mg Q4W - TP 1 - LPP Cohort	37.6
Placebo - TP 1 - LPP Cohort	30.9

The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Week 2 0 score	Week 16 0 score	Week 16 1 score	Week 16 2 score	Week 16 3 score	Week 16 4 score	Week 16 5 score	Week 20 0 score	Week 20 1 score	Week 20 2 score	Week 20 3 score	Week 20 4 score	Week 20 5 score	Week 24 0 score	Week 24 1 score	Week 24 2 score	Week 24 3 score	Week 24 4 score	Week 24 5 score	Week 28 0 score	Week 28 1 score	Week 28 2 score	Week 28 3 score	Week 28 4 score	Week 28 5 score	Week 32 0 score	Week 32 1 score	Week 32 2 score	Week 32 3 score	Week 32 4 score	Week 32 5 score
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort	0	0	0	3	3	4	0	0	0	3	2	3	2	0	0	2	2	4	2	0	0	2	3	3	2	0	1	0	4	2	2

Intervention	Participants (Count of Participants)
	Baseline 0 Score	Baseline 1 score	Baseline 2 score	Baseline 3 score	Baseline 4 score	Baseline 5 score	Week 2 0 score	Week 2 1 score	Week 2 2 score	Week 2 3 score	Week 2 4 score	Week 2 5 score	Week 4 0 score	Week 4 1 score	Week 4 2 score	Week 4 3 score	Week 4 4 score	Week 4 5 score	Week 8 0 score	Week 8 1 score	Week 8 2 score	Week 8 3 score	Week 8 4 score	Week 8 5 score	Week 12 0 score	Week 12 1 score	Week 12 2 score	Week 12 3 score	Week 12 4 score	Week 12 5 score	Week 16 0 score	Week 16 1 score	Week 16 2 score	Week 16 3 score	Week 16 4 score	Week 16 5 score
Placebo - TP 1 - CLP Cohort	0	0	0	3	6	3	0	0	1	3	5	3	0	0	0	3	5	3	0	1	1	2	4	3	0	1	2	0	7	2	0	2	3	3	4	0

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline 0 Score	Baseline 1 score	Baseline 2 score	Baseline 3 score	Baseline 4 score	Baseline 5 score	Week 2 0 score	Week 2 1 score	Week 2 2 score	Week 2 3 score	Week 2 4 score	Week 2 5 score	Week 4 0 score	Week 4 1 score	Week 4 2 score	Week 4 3 score	Week 4 4 score	Week 4 5 score	Week 8 0 score	Week 8 1 score	Week 8 2 score	Week 8 3 score	Week 8 4 score	Week 8 5 score	Week 12 0 score	Week 12 1 score	Week 12 2 score	Week 12 3 score	Week 12 4 score	Week 12 5 score	Week 16 0 score	Week 16 1 score	Week 16 2 score	Week 16 3 score	Week 16 4 score	Week 16 5 score	Week 20 0 score	Week 20 1 score	Week 20 2 score	Week 20 3 score	Week 20 4 score	Week 20 5 score	Week 24 0 score	Week 24 1 score	Week 24 2 score	Week 24 3 score	Week 24 4 score	Week 24 5 score	Week 28 0 score	Week 28 1 score	Week 28 2 score	Week 28 3 score	Week 28 4 score	Week 28 5 score	Week 32 0 score	Week 32 1 score	Week 32 2 score	Week 32 3 score	Week 32 4 score	Week 32 5 score
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort	0	3	6	6	5	5	0	6	5	9	3	2	0	3	8	8	3	2	0	7	5	7	4	2	0	6	7	7	3	2	0	4	12	5	2	2	0	6	12	3	1	2	1	8	10	1	2	3	0	6	11	1	3	2	2	5	10	3	1	3

"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline n=25,12,0	Week 4 n=24,11,0	Week 8 n=25,11,0	Week 12 n=25,12,0	Week 16 n=25,12,10
Placebo - TP 1 - CLP Cohort	0	0	0	1	2

Intervention	Participants (Count of Participants)
	Week 16 n=25,12,10	Week 20 n=24,0,10	Week 24 n=25,0,10	Week 28 n=23,0,10	Week 32 n=25,0,9
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort	2	1	1	1	1

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline n=25,12,0	Week 4 n=24,11,0	Week 8 n=25,11,0	Week 12 n=25,12,0	Week 16 n=25,12,10	Week 20 n=24,0,10	Week 24 n=25,0,10	Week 28 n=23,0,10	Week 32 n=25,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort	0	2	2	3	3	3	4	3	2

"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline n=24,13,0	Week 4 n=24,13,0	Week 8 n=24,13,0	Week 12 n=24,13,0	Week 16 n=24,13,13
Placebo - TP 1 - LPP Cohort	0	1	1	2	1

Intervention	Participants (Count of Participants)
	Week 16 n=24,13,13	Week 20 n=24,0,13	Week 24 n=23,0,13	Week 28 n=24,0,13	Week 32 n=24,0,11
Placebo to AIN457 300 mg Q2W TP 2 - LPP Cohort	1	3	3	2	3

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline n=24,13,0	Week 4 n=24,13,0	Week 8 n=24,13,0	Week 12 n=24,13,0	Week 16 n=24,13,13	Week 20 n=24,0,13	Week 24 n=23,0,13	Week 28 n=24,0,13	Week 32 n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort	0	3	3	2	2	4	2	2	1

Intervention	Participants (Count of Participants)
	Baseline n=24,13,0	Week 4 n=24,13,0	Week 8 n=24,13,0	Week 12 n=24,13,0	Week 16 n=24,13,11
Placebo - TP 1 - MLP Cohort	0	1	1	2	3

Intervention	Participants (Count of Participants)
	Week 16 n=24,13,11	Week 20 n=24,0,11	Week 24 n=24,0,10	Week 28 n=23,0,11	Week 32 n=23,0,10
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	2	2	3	2	2

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Baseline n=24,13,0	Week 4 n=24,13,0	Week 8 n=24,13,0	Week 12 n=24,13,0	Week 16 n=24,13,11	Week 20 n=24,0,11	Week 24 n=24,0,10	Week 28 n=23,0,11	Week 32 n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2- MLP Cohort	0	2	4	4	5	7	7	3	4

Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=25,12,0	Week 2 IGA improvement >=2 n=25,12,0	Week 2 IGA 0/1 n=25,12,0	Week 4 IGA <=2 n=24,11,0	Week 4 IGA improvement. >=2 n=24,11,0	Week 4 IGA 0/1 n=24,11,0	Week 8 IGA <=2 n=25,11,0	Week 8 IGA improvement. >=2 n=25,11,0	Week 8 IGA 0/1 n=25,11,0	Week 12 IGA <=2 n=25,12,0	Week 12 IGA improvement. >=2 n=25,12,0	Week 12 IGA 0/1 n=25,12,0	Week16 IGA <=2 n=25,12,10	Week 16 IGA improvement. >=2 n=25,12,10	Week 16 IGA 0/1 n=25,12,10
Placebo - TP 1 - CLP Cohort	1	0	0	2	0	0	3	1	1	4	2	1	7	3	2

Intervention	Participants (Count of Participants)
	Week16 IGA <=2 n=25,12,10	Week 16 IGA improvement. >=2 n=25,12,10	Week 16 IGA 0/1 n=25,12,10	Week 20 IGA <=2 n=24,0,10	Week 20 IGA improvement. >=2 n=24,0,10	Week 20 IGA 0/1 n=24,0,10	Week 24 IGA <=2 n=25,0,10	Week 24 IGA improvement. >=2 n=25,0,10	Week 24 IGA 0/1 n=25,0,10	Week 28 IGA <=2 n=23,0,10	Week 28 IGA improvement. >=2 n=23,0,10	Week 28 IGA 0/1 n=23,0,10	Week 32 IGA <=2 n=24,0,9	Week 32 IGA improvement. >=2 n=24,0,9	Week 32 IGA 0/1 n=24,0,9
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort	5	1	0	1	1	1	3	2	1	4	1	1	2	2	1

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=25,12,0	Week 2 IGA improvement >=2 n=25,12,0	Week 2 IGA 0/1 n=25,12,0	Week 4 IGA <=2 n=24,11,0	Week 4 IGA improvement. >=2 n=24,11,0	Week 4 IGA 0/1 n=24,11,0	Week 8 IGA <=2 n=25,11,0	Week 8 IGA improvement. >=2 n=25,11,0	Week 8 IGA 0/1 n=25,11,0	Week 12 IGA <=2 n=25,12,0	Week 12 IGA improvement. >=2 n=25,12,0	Week 12 IGA 0/1 n=25,12,0	Week16 IGA <=2 n=25,12,10	Week 16 IGA improvement. >=2 n=25,12,10	Week 16 IGA 0/1 n=25,12,10	Week 20 IGA <=2 n=24,0,10	Week 20 IGA improvement. >=2 n=24,0,10	Week 20 IGA 0/1 n=24,0,10	Week 24 IGA <=2 n=25,0,10	Week 24 IGA improvement. >=2 n=25,0,10	Week 24 IGA 0/1 n=25,0,10	Week 28 IGA <=2 n=23,0,10	Week 28 IGA improvement. >=2 n=23,0,10	Week 28 IGA 0/1 n=23,0,10	Week 32 IGA <=2 n=24,0,9	Week 32 IGA improvement. >=2 n=24,0,9	Week 32 IGA 0/1 n=24,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort	5	2	2	9	3	2	10	4	3	10	3	4	11	4	4	11	5	5	14	10	10	12	7	6	9	7	6

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=24,13,0	Week 2 IGA improvement >=2 n=24,13,0	Week 2 IGA 0/1 n=24,13,0	Week 4 IGA <=2 n=24,13,0	Week 4 IGA improvement. >=2 n=24,13,0	Week 4 IGA 0/1 n=24,13,0	Week 8 IGA <=2 n=24,13,0	Week 8 IGA improvement. >=2 n=24,13,0	Week 8 IGA 0/1 n=24,13,0	Week 12 IGA <=2 n=24,13,0	Week 12 IGA improvement. >=2 n=24,13,0	Week 12 IGA 0/1 n=24,13,0	Week16 IGA <=2 n=24,13,13	Week 16 IGA improvement. >=2 n=24,13,13	Week 16 IGA 0/1 n=24,13,13
Placebo - TP 1 - LPP Cohort	1	0	0	2	1	1	3	1	1	4	2	2	4	0	0

Intervention	Participants (Count of Participants)
	Week16 IGA <=2 n=24,13,13	Week 16 IGA improvement. >=2 n=24,13,13	Week 16 IGA 0/1 n=24,13,13	Week 20 IGA <=2 n=24,0,13	Week 20 IGA improvement. >=2 n=24,0,13	Week 20 IGA 0/1 n=24,0,13	Week 24 IGA <=2 n=23,0,13	Week 24 IGA improvement. >=2 n=23,0,13	Week 24 IGA 0/1 n=23,0,13	Week 28 IGA <=2 n=24,0,13	Week 28 IGA improvement. >=2 n=24,0,13	Week 28 IGA 0/1 n=24,0,13	Week 32 IGA <=2 n==24,0,11	Week 32 IGA improvement. >=2 n==24,0,11	Week 32 IGA 0/1 n==24,0,11
Placebo to AIN457 300 mg Q2W - TP 2- LPP Cohort	4	0	0	6	1	0	8	3	2	9	4	3	7	5	4

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=24,13,0	Week 2 IGA improvement >=2 n=24,13,0	Week 2 IGA 0/1 n=24,13,0	Week 4 IGA <=2 n=24,13,0	Week 4 IGA improvement. >=2 n=24,13,0	Week 4 IGA 0/1 n=24,13,0	Week 8 IGA <=2 n=24,13,0	Week 8 IGA improvement. >=2 n=24,13,0	Week 8 IGA 0/1 n=24,13,0	Week 12 IGA <=2 n=24,13,0	Week 12 IGA improvement. >=2 n=24,13,0	Week 12 IGA 0/1 n=24,13,0	Week16 IGA <=2 n=24,13,13	Week 16 IGA improvement. >=2 n=24,13,13	Week 16 IGA 0/1 n=24,13,13	Week 20 IGA <=2 n=24,0,13	Week 20 IGA improvement. >=2 n=24,0,13	Week 20 IGA 0/1 n=24,0,13	Week 24 IGA <=2 n=23,0,13	Week 24 IGA improvement. >=2 n=23,0,13	Week 24 IGA 0/1 n=23,0,13	Week 28 IGA <=2 n=24,0,13	Week 28 IGA improvement. >=2 n=24,0,13	Week 28 IGA 0/1 n=24,0,13	Week 32 IGA <=2 n==24,0,11	Week 32 IGA improvement. >=2 n==24,0,11	Week 32 IGA 0/1 n==24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort	4	1	1	9	2	2	8	3	3	8	3	2	9	3	2	10	6	4	10	7	6	10	6	5	11	5	4

Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=24,12,0	Week 2 IGA improvement >=2 n=24,12,0	Week 2 IGA 0/1 n=24,12,0	Week 4 IGA <=2 n=24,13,0	Week 4 IGA improvement. >=2 n=24,13,0	Week 4 IGA 0/1 n=24,13,0	Week 8 IGA <=2 n=24,13,0	Week 8 IGA improvement. >=2 n=24,13,0	Week 8 IGA 0/1 n=24,13,0	Week 12 IGA <=2 n=24,13,0	Week 12 IGA improvement. >=2 n=24,13,0	Week 12 IGA 0/1 n=24,13,0	Week16 IGA <=2 n=24,13,11	Week 16 IGA improvement. >=2 n=24,13,11	Week 16 IGA 0/1 n=24,13,11
Placebo - TP 1 - MLP Cohort	3	1	1	2	1	1	3	2	1	4	4	2	3	3	2

Intervention	Participants (Count of Participants)
	Week16 IGA <=2 n=24,13,11	Week 16 IGA improvement. >=2 n=24,13,11	Week 16 IGA 0/1 n=24,13,11	Week 20 IGA <=2 n=24,0,11	Week 20 IGA improvement. >=2 n=24,0,11	Week 20 IGA 0/1 n=24,0,11	Week 24 IGA <=2 n=24,0,10	Week 24 IGA improvement. >=2 n=24,0,10	Week 24 IGA 0/1 n=24,0,10	Week 28 IGA <=2 n=23,0,11	Week 28 IGA improvement. >=2 n=23,0,11	Week 28 IGA 0/1 n=23,0,11	Week 32 IGA <=2 n=23,0,10	Week 32 IGA improvement. >=2 n=23,0,10	Week 32 IGA 0/1 n=23,0,10
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	1	1	0	3	2	1	4	2	0	4	3	0	2	1	0

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

Intervention	Participants (Count of Participants)
	Week 2 IGA <=2 n=24,12,0	Week 2 IGA improvement >=2 n=24,12,0	Week 2 IGA 0/1 n=24,12,0	Week 4 IGA <=2 n=24,13,0	Week 4 IGA improvement. >=2 n=24,13,0	Week 4 IGA 0/1 n=24,13,0	Week 8 IGA <=2 n=24,13,0	Week 8 IGA improvement. >=2 n=24,13,0	Week 8 IGA 0/1 n=24,13,0	Week 12 IGA <=2 n=24,13,0	Week 12 IGA improvement. >=2 n=24,13,0	Week 12 IGA 0/1 n=24,13,0	Week16 IGA <=2 n=24,13,11	Week 16 IGA improvement. >=2 n=24,13,11	Week 16 IGA 0/1 n=24,13,11	Week 20 IGA <=2 n=24,0,11	Week 20 IGA improvement. >=2 n=24,0,11	Week 20 IGA 0/1 n=24,0,11	Week 24 IGA <=2 n=24,0,10	Week 24 IGA improvement. >=2 n=24,0,10	Week 24 IGA 0/1 n=24,0,10	Week 28 IGA <=2 n=23,0,11	Week 28 IGA improvement. >=2 n=23,0,11	Week 28 IGA 0/1 n=23,0,11	Week 32 IGA <=2 n=23,0,10	Week 32 IGA improvement. >=2 n=23,0,10	Week 32 IGA 0/1 n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort	5	1	1	4	1	1	5	0	0	5	5	4	9	5	4	10	5	5	10	3	3	7	1	1	9	2	2

The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline n=24,13,13	Week 16 n=24,13,13
Placebo - TP 1 - LPP Cohort	5.95	-2.24

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline n=24,13,13	Week 16 n=24,13,13	Week 32 n=24,0,13
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort	5.92	-1.44	-2.44
Placebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort	5.95	-2.24	-3.20

"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1	Week 16 Severity of itch during past 24 hours n=25,12,10	Baseline- Question 2	Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10	Baseline- Question 3	Week 16 How bothered by Itch during past 24 hours n=25,12,10
Placebo - TP 1 - CLP Cohort	5.7	-2.3	6.3	-2.7	6.1	-2.7

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1	Week 16 Severity of itch during past 24 hours n=25,12,10	Week 32 Severity of itch during past 24 hours n=25,0,9	Baseline- Question 2	Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10	Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9	Baseline- Question 3	Week 16 How bothered by Itch during past 24 hours n=25,12,10	Week 32 How bothered by Itch during past 24 hours n=25,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort	5.1	-0.8	-1.5	5.6	-0.9	-1.3	4.8	-1.0	-1.1
Placebo to AIN457 300 mg Q2W TP 2 - CLP Cohort	5.8	-2.0	-1.1	5.9	-1.9	-1.2	6.1	-2.4	-1.2

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,13	Week 16 Severity of itch during past 24 hours n=24,13,11	Baseline - Question 2 n=24,13,13	Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13	Baseline - Question 3 n=24,13,11	Week 16 How bothered by Itch during past 24 hours n=24,13,13
Placebo - TP 1 - LPP Cohort	3.8	-1.1	4.2	-1.3	3.2	-1.2

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,13	Week 16 Severity of itch during past 24 hours n=24,13,11	Week 32 Severity of itch during past 24 hours n=24,0,11	Baseline - Question 2 n=24,13,13	Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13	Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11	Baseline - Question 3 n=24,13,11	Week 16 How bothered by Itch during past 24 hours n=24,13,13	Week 32 How bothered by Itch during past 24 hours n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort	4.5	-0.5	-1.6	5.1	-0.7	-1.8	4.0	-0.4	-1.7
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort	3.8	-1.1	-2.4	4.1	-1.3	-2.6	3.2	-1.2	-2.2

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=23,13,11	Week 16 Severity of itch during past 24 hours n=23,13,11	Baseline - Question 2 n=23,13,11	Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11	Baseline - Question 3 n=24,13,11	Week 16 How bothered by Itch during past 24 hours n=23,13,11
Placebo - TP 1 - MLP Cohort	3.8	-0.2	3.6	0.4	4.0	0.1

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=23,13,11	Week 16 Severity of itch during past 24 hours n=23,13,11	Week 32 Severity of itch during past 24 hours n=22,0,10	Baseline - Question 2 n=23,13,11	Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11	Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10	Baseline - Question 3 n=24,13,11	Week 16 How bothered by Itch during past 24 hours n=23,13,11	Week 32 How bothered by Itch during past 24 hours n=22,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort	2.5	0.3	0.1	2.4	0.8	0.3	3.4	-0.5	-0.2
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	4.3	-0.3	-0.4	4.1	0.4	0.4	4.5	0.0	-0.4

"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=25,12,10	Week 16 Severity of pain during past 24 hours n=25,12,10	Baseline - Question 2 n=25,12,10	Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10	Baseline - Question 3 n=25,12,10	Week 16 How bothered by pain during past 24 hour n=25,12,10
Placebo - TP 1 - CLP Cohort	3.4	-0.8	3.9	-1.2	3.7	-0.6

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=25,12,10	Week 16 Severity of pain during past 24 hours n=25,12,10	Week 32 Severity of pain during past 24 hours n=25,0,9	Baseline - Question 2 n=25,12,10	Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10	Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9	Baseline - Question 3 n=25,12,10	Week 16 How bothered by pain during past 24 hour n=25,12,10	Week 32 How bothered by pain during past 24 hours n=25, 0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort	1.09	0.2	-0.3	2.2	0.1	-0.4	2.1	0.1	-0.2
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort	3.5	-0.8	-0.3	3.9	-1.0	-0.4	3.8	0.5	-0.3

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,12	Week 16 Severity of pain during past 24 hours n=24,13,12	Baseline - Question 2 24,13,12	Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12	Baseline - Question 3 n=24,13,12	Week 16 How bothered by pain during past 24 hour n=24,13,12
Placebo - TP 1 - LPP Cohort	2.0	-0.5	2.5	-0.9	2.4	-1.1

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,12	Week 16 Severity of pain during past 24 hours n=24,13,12	Week 32 Severity of pain during past 24 hours n=24,0,11	Baseline - Question 2 24,13,12	Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12	Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11	Baseline - Question 3 n=24,13,12	Week 16 How bothered by pain during past 24 hour n=24,13,12	Week 32 How bothered by pain during past 24 hours n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort	2.5	0.3	-0.6	2.8	0.2	-0.8	2.7	0.0	-0.8
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort	2.0	-0.5	-1.5	2.5	-0.9	-2.0	2.4	-1.1	-1.9

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,11	Week 16 Severity of pain during past 24 hours n=24,13,11	Baseline - Question 2 n=24,13,11	Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11	Baseline - Question 3 n=24,13,11	Week 16 How bothered by pain during past 24 hour n=24,13,11
Placebo - TP 1 - MLP Cohort	5.9	-0.1	6.4	-0.3	6.5	-0.3

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline - Question 1 n=24,13,11	Week 16 Severity of pain during past 24 hours n=24,13,11	Week 32 Severity of pain during past 24 hours n=23,0,10	Baseline - Question 2 n=24,13,11	Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11	Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10	Baseline - Question 3 n=24,13,11	Week 16 How bothered by pain during past 24 hour n=24,13,11	Week 32 How bothered by pain during past 24 hours n=23,0,10
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort	5.1	-0.5	-0.3	5.4	-0.5	-0.3	5.5	-0.8	-0.5
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	6.3	0.0	-0.6	6.7	-0.2	-0.5	6.8	-0.1	-0.9

Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Intervention	scores on a scale (Mean)
	Baseline n=24,13,12	Week 16 n=24,13,12
Placebo - TP 1 - LPP Cohort	54.01	-6.94

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

Intervention	scores on a scale (Mean)
	Baseline n=24,13,12	Week 16 n=24,13,12	Week 32 n=24,0,11
AIN457 300 mg Q4W - TP 1 and TP 2 -LPP Cohort	55.75	1.86	-4.26
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort	54.01	-6.94	-14.43

OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

Intervention	scores on a scale (Mean)
	Baseline n=21,12,10	Week 16 n=21,12,10
Placebo - TP 1 - MLP Cohort	13.4	0.8

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

Intervention	scores on a scale (Mean)
	Baseline n=21,12,10	Week 16 n=21,12,10	Week 32 n=20,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort	11.0	-1.0	-1.8
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	13.9	-0.4	-0.7

REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

Intervention	scores on a scale (Mean)
	Baseline n=21,12,10	Week 16 n=21,12,10
Placebo - TP 1 - MLP Cohort	25.29	-5.79

Average Steps Per Day Assessed by FitBit® / Pedometer

Intervention	scores on a scale (Mean)
	Baseline n=21,12,10	Week 16 n=21,12,10	Week 32 n=20,0,9
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort	21.31	-4.83	-6.08
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort	26.95	-4.10	-2.17

Average number of steps walked per day from baseline to the end of each treatment. (NCT02960997)
Timeframe: 12 weeks

Trough Concentration of Sirolimus

Intervention	steps (Mean)
Sirolimus	6624
Placebo	7130

Trough measurements were taken prior to topical sirolimus administration at the week 12 study visit. (NCT02960997)
Timeframe: Week 12

5-D Pruritus Scale Score

Intervention	ng/mL (Mean)
Sirolimus	NA

The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected). Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period

Child Dermatological Quality of Life Questionnaire Score

Intervention	score on a scale (Mean)
	Week 0	Week 12
Placebo	11.5	11.8
Sirolimus	12.8	12.5

Quality of Life-Epidermolysis Bullosa (QOLEB) Questionnaire specifically designed for people with EB. The QOLEB can be used to identify everyday life occurrences negatively affected by EB. It assesses change in quality of life over time, an important measure when assessing the success of new treatments for EB. Scores from 0 to 51, with higher scores indicate greater impact of EB on quality of life. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period

Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale Score

Intervention	score on a scale (Mean)
	Week 0	Week 12
Placebo	6.6	13.3
Sirolimus	14.1	14.5

The EBDASI is a validated scoring system that objectively quantifies the severity of EB affecting the entire body. It has been designed to evaluate the response to new therapies for the treatment of EB. Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period

Foot Health Status Questionnaire, Foot Function Domain Score

Foot function was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period

Foot Health Status Questionnaire, Physical Activity Domain Score

Physical Activity was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period

Article	Year
Treatment of Alopecia in Children. Journal of drugs in dermatology : JDD, 2022, Jan-01, Volume: 21, Issue:1 Topics: Alopecia; Biopsy; Child; Cicatrix; Hair; Humans; Scalp	2022
Natural results of scalp micropigmentation: A review. Journal of cosmetic dermatology, 2022, Volume: 21, Issue:11 Topics: Alopecia; Cicatrix; Humans; Scalp; Skin Transplantation	2022
EROSIVE PUSTULAR DERMATOSIS OF THE SCALP (EPDS) - A CASE SERIES AND SHORT REVIEW. Georgian medical news, 2023, Issue:334 Topics: Aged; Alopecia; Cicatrix; Communicable Diseases; Humans; Scalp; Skin	2023
Scarring Alopecia. Dermatologic clinics, 2023, Volume: 41, Issue:3 Topics: Alopecia; Cicatrix; Hair; Humans; Lupus Erythematosus, Discoid; Scalp	2023
The role of the scalp biopsy in the evaluation of alopecia. Journal of the American Academy of Dermatology, 2023, Volume: 89, Issue:2S Topics: Alopecia; Biopsy; Cicatrix; Hair; Humans; Scalp	2023
PPAR-γ signalling as a key mediator of human hair follicle physiology and pathology. Experimental dermatology, 2020, Volume: 29, Issue:3 Topics: Alopecia; Animals; Cicatrix; Epithelial-Mesenchymal Transition; Hair; Hair Diseases; Hair Follicle;	2020
[Alopecia-keep a cool head]. Der Pathologe, 2020, Volume: 41, Issue:4 Topics: Alopecia; Biopsy; Cicatrix; Humans; Scalp	2020
A proposed mechanism for central centrifugal cicatricial alopecia. Experimental dermatology, 2020, Volume: 29, Issue:2 Topics: Alopecia; Cicatrix; Fibrosis; Humans; Kidney; Kidney Diseases; Lichen Planus; PPAR gamma; Scalp; Scl	2020
Morphea «En Coup De Sabre» at the Site of Healed Herpes Zoster Ophthalmicus. Actas dermo-sifiliograficas, 2019, Volume: 110, Issue:7 Topics: Adult; Alopecia; Cicatrix; Facial Dermatoses; Female; Forehead; Herpes Zoster Ophthalmicus; Humans;	2019
Nonshaven Follicular Unit Extraction: Personal Experience. Annals of plastic surgery, 2019, Volume: 82, Issue:3 Topics: Adult; Alopecia; Cicatrix; Esthetics; Female; Graft Survival; Hair; Hair Follicle; Humans; Male; Mid	2019
The Applications of Medical Tattooing in the Head and Neck Region. Facial plastic surgery : FPS, 2019, Volume: 35, Issue:3 Topics: Alopecia; Cicatrix; Humans; Quality of Life; Scalp; Tattooing	2019
Graham-Little-Piccardi-Lasseur syndrome: case report and review of the syndrome in men. International journal of dermatology, 2014, Volume: 53, Issue:8 Topics: Abnormalities, Multiple; Adult; Alopecia; Axilla; Cicatrix; Darier Disease; Eyebrows; Humans; Lichen	2014
Primary cicatricial alopecia: diagnosis and treatment. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Dec-10, Volume: 185, Issue:18 Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Disease Management; Humans; Scalp	2013
Graft harvesting and management of the donor site. Facial plastic surgery clinics of North America, 2013, Volume: 21, Issue:3 Topics: Alopecia; Cicatrix; Cosmetic Techniques; Dermatologic Surgical Procedures; Hair; Hair Follicle; Huma	2013
Hair loss in autoimmune systemic diseases. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:1 Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Cicatrix; Connective Tissue Diseases; Hair Diseases;	2014
Trichoscopy: an update. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2014, Volume: 149, Issue:1 Topics: Alopecia; Black People; Cicatrix; Dermoscopy; Hair; Hair Diseases; Humans; Lice Infestations; Refere	2014
Complications in tissue expansion: an updated retrospective analysis of risk factors. Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2014, Volume: 46, Issue:2 Topics: Adolescent; Adult; Child; Cicatrix; Extremities; Face; Female; Hand; Humans; Male; Middle Aged; Neck	2014
Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research. Dermatologic clinics, 2014, Volume: 32, Issue:2 Topics: Alopecia Areata; Black or African American; Cicatrix; Female; Humans; Prevalence; Risk Factors; Scal	2014
Follicular and scarring disorders in skin of color: presentation and management. American journal of clinical dermatology, 2014, Volume: 15, Issue:4 Topics: Alopecia; Cicatrix; Hair Follicle; Humans; Quality of Life; Racial Groups; Scalp; Skin Diseases; Ski	2014
Scalp dermoscopy or trichoscopy. Current problems in dermatology, 2015, Volume: 47 Topics: Alopecia; Alopecia Areata; Cicatrix; Dermoscopy; Hair Diseases; Humans; Lupus Erythematosus, Discoid	2015
Primary scarring alopecias. Current problems in dermatology, 2015, Volume: 47 Topics: Acne Keloid; Alopecia; Cellulitis; Cicatrix; Fibrosis; Folliculitis; Humans; Lichen Planus; Lupus Er	2015
Diagnosis and management of hair loss in children. Current opinion in pediatrics, 2016, Volume: 28, Issue:4 Topics: Age Factors; Child; Cicatrix; Dermoscopy; Diagnosis, Differential; Hair Diseases; Humans; Medical Hi	2016
Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. European journal of dermatology : EJD, 2016, Aug-01, Volume: 26, Issue:4 Topics: Alopecia; Biopsy; Cicatrix; Humans; Microtomy; Scalp; Skin	2016
Primary scalp alopecia: new histopathological tools, new concepts and a practical guide to diagnosis. Journal of cutaneous pathology, 2017, Volume: 44, Issue:1 Topics: Alopecia; Cicatrix; Female; Humans; Male; Scalp	2017
Treatment of Scalp Scars. Facial plastic surgery clinics of North America, 2017, Volume: 25, Issue:1 Topics: Cicatrix; Humans; Plastic Surgery Procedures; Scalp; Skin Transplantation; Surgical Flaps; Tissue Ex	2017
Hair transplantation for men. Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology, 2008, Volume: 10, Issue:3 Topics: Alopecia; Cicatrix; Cosmetic Techniques; Finasteride; Hair; Hair Follicle; Humans; Low-Level Light T	2008
Iatrogenic skin injury in the neonatal intensive care unit. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2011, Volume: 24, Issue:2 Topics: Burns; Cicatrix; Humans; Iatrogenic Disease; Infant, Extremely Low Birth Weight; Infant, Newborn; In	2011
Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle. Journal of the American Academy of Dermatology, 2010, Volume: 63, Issue:6 Topics: Alopecia; Anemia, Iron-Deficiency; Animals; Cicatrix; Female; Humans; Iron; Scalp	2010
The coronal scalp flap: surgical technique. Atlas of the oral and maxillofacial surgery clinics of North America, 2010, Volume: 18, Issue:2 Topics: Blood Loss, Surgical; Cicatrix; Electrocoagulation; Facial Nerve Injuries; Humans; Plastic Surgery P	2010
Burn reconstruction. Physical medicine and rehabilitation clinics of North America, 2011, Volume: 22, Issue:2 Topics: Alopecia; Burns; Cicatrix; Contracture; Face; Humans; Lower Extremity; Mammaplasty; Perineum; Pigmen	2011
Sarcoidosis-induced alopecia. Dermatology online journal, 2012, Aug-15, Volume: 18, Issue:8 Topics: Alopecia; Black or African American; Cicatrix; Female; Humans; Male; Middle Aged; Sarcoidosis; Scalp	2012
Histopathology of scarring and nonscarring hair loss. Dermatologic clinics, 2013, Volume: 31, Issue:1 Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Hair Diseases; Hair Follicle; Humans; Microtomy	2013
Hair sparing techniques and scalp flap design. Neurosurgery clinics of North America, 2002, Volume: 13, Issue:4 Topics: Cicatrix; Hair; Humans; Plastic Surgery Procedures; Scalp; Skull; Surgical Flaps	2002
Intricacies of the single-scar technique for donor harvesting in hair transplantation surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:6 Topics: Cicatrix; Hair Follicle; Humans; Plastic Surgery Procedures; Scalp	2004
Cicatricial eyebrow reconstruction with a dense-packing one- to two-hair grafting technique. Plastic and reconstructive surgery, 2004, Volume: 114, Issue:6 Topics: Adolescent; Adult; Burns; Burns, Chemical; Child; Cicatrix; Esthetics; Eyebrows; Facial Injuries; Fe	2004
Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN). Acta dermato-venereologica, 2006, Volume: 86, Issue:5 Topics: Alopecia; Breast Neoplasms; Carcinoma, Basal Cell; Cicatrix; Hemangiosarcoma; Humans; Keloid; Lympho	2006
Minimal scars for scalp surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007, Volume: 33, Issue:1 Topics: Cicatrix; Humans; Postoperative Complications; Scalp; Skin; Suture Techniques; Wound Healing	2007
The management of postacne scarring. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2007, Volume: 33, Issue:10 Topics: Acne Vulgaris; Cicatrix; Face; Humans; Keratolytic Agents; Scalp; Severity of Illness Index	2007
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis, 2008, Volume: 81, Issue:2 Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp	2008
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis, 2008, Volume: 81, Issue:2 Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp	2008
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis, 2008, Volume: 81, Issue:2 Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp	2008
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis, 2008, Volume: 81, Issue:2 Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp	2008
[Cicatricial alopecias: diagnosis and therapy]. Praxis, 1997, Jun-04, Volume: 86, Issue:23 Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Hair Follicle; Humans; Prognosis; Scalp	1997
Sarcoma developing in a burn scar: case report and review of the literature. Burns : journal of the International Society for Burn Injuries, 1998, Volume: 24, Issue:1 Topics: Adult; Burns; Cell Transformation, Neoplastic; Cicatrix; Humans; Leiomyosarcoma; Male; Scalp; Skin N	1998
Scarring alopecia and the dermatopathologist. Journal of cutaneous pathology, 2001, Volume: 28, Issue:7 Topics: Alopecia; Biopsy; Cicatrix; Dermatology; Diagnosis, Differential; Humans; Scalp	2001
Hair transplantation: management of donor area. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2002, Volume: 28, Issue:2 Topics: Cicatrix; Hair Follicle; Humans; Scalp; Suture Techniques; Wound Healing	2002

Article	Year
Combination treatment with 30% salicylic acid and fractional CO Dermatologic therapy, 2022, Volume: 35, Issue:9 Topics: Acne Vulgaris; Carbon Dioxide; Cicatrix; Humans; Lasers, Gas; Pain; Prospective Studies; Salicylic A	2022
High-voltage electric stimulation of the donor site of skin grafts accelerates the healing process. A randomized blinded clinical trial. Burns : journal of the International Society for Burn Injuries, 2018, Volume: 44, Issue:3 Topics: Adult; Burns; Cicatrix; Double-Blind Method; Electric Stimulation Therapy; Female; Humans; Male; Mid	2018
Treatment of Postsurgical Scalp Scar Deformity Using Follicular Unit Hair Transplantation. BioMed research international, 2019, Volume: 2019 Topics: Adolescent; Adult; Alopecia; Cicatrix; Female; Hair Follicle; Humans; Male; Scalp	2019
[Clinical study of repairing donor site of thickness from cicatricial skin with auto-scalp grafting]. Zhonghua yi xue za zhi, 2013, Mar-26, Volume: 93, Issue:12 Topics: Adult; Burns; Cicatrix; Female; Humans; Male; Middle Aged; Scalp; Skin Transplantation; Transplantat	2013
Invisible scar endoscopic dorsal approach thyroidectomy: a clinical feasibility study. World journal of surgery, 2010, Volume: 34, Issue:12 Topics: Adult; Cicatrix; Endoscopy; Feasibility Studies; Female; Humans; Male; Middle Aged; Prospective Stud	2010
Comparison of suture types in the closure of scalp wounds. Emergency nurse : the journal of the RCN Accident and Emergency Nursing Association, 2011, Volume: 19, Issue:3 Topics: Adult; Aged; Biocompatible Materials; Cicatrix; Female; Humans; Lacerations; Male; Middle Aged; Scal	2011
Treatment of actinic keratoses and photodamage with non-contact fractional 1540-nm laser quasi-ablation: an ex vivo and clinical evaluation. Lasers in medical science, 2013, Volume: 28, Issue:2 Topics: Aged; Cicatrix; Edema; Erythema; Face; Female; Humans; Keratosis, Actinic; Laser Therapy; Lasers, So	2013
The influence of peri-incisional triamcinolone acetonide injection on wound edge apposition. The Journal of dermatological treatment, 2014, Volume: 25, Issue:4 Topics: Adult; Cicatrix; Female; Glucocorticoids; Hair; Humans; Injections, Intradermal; Male; Middle Aged;	2014
Consecutive wide and long single hair-bearing transposition flaps in combination with hair transplantation for the management of slot formation after alopecia reducing surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 1996, Volume: 22, Issue:4 Topics: Alopecia; Cicatrix; Esthetics; Hair; Hair Diseases; Humans; Postoperative Complications; Scalp; Surg	1996
Reconstruction of burn deformity using artificial dermis combined with thin split-skin grafting. Burns : journal of the International Society for Burn Injuries, 1997, Volume: 23, Issue:6 Topics: Adolescent; Adult; Burns; Child; Child, Preschool; Cicatrix; Contracture; Female; Graft Survival; Hu	1997
Outcomes of irradiated polyglactin 910 Vicryl Rapide fast-absorbing suture in oral and scalp wounds. Journal (Canadian Dental Association), 1999, Volume: 65, Issue:6 Topics: Adult; Biocompatible Materials; Cicatrix; Humans; Lactic Acid; Mouth; Oral Surgical Procedures; Poly	1999
[Local administration of drug during tissue expansion]. Zhonghua zheng xing shao shang wai ke za zhi = Zhonghua zheng xing shao shang waikf [i.e. waike] zazhi = Chinese journal of plastic surgery and burns, 1997, Volume: 13, Issue:5 Topics: Adolescent; Adult; Anesthetics, Local; Child; Cicatrix; Female; Glucocorticoids; Humans; Male; Middl	1997
A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study). Annals of emergency medicine, 2002, Volume: 40, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cicatrix; Female; Follow-Up Stu	2002
Absorbable versus nonabsorbable sutures to prevent postoperative stretching of wound area. Plastic and reconstructive surgery, 1986, Volume: 78, Issue:2 Topics: Absorption; Adult; Benzenesulfonates; Cicatrix; Humans; Polypropylenes; Random Allocation; Scalp; Su	1986

salicylic acid and Cicatrization

Research Excerpts

Research

Studies (356)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Response Rate of Investigator Global Assessment (IGA) Score of 2 or Lower at Week 16 for CLP, MLP and LPP

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

Number (%) of Subjects in Each Category in Physician´s Assessment of Surface Area of Disease (PSAD) - CLP (BOCF) - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - CLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - LPP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With Dermatology Life Quality Index Response Scores of 0 to 1 up to Week 32 - MLP Cohort - Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - CLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - LPP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Number (%) of Subjects With IGA ≤ 2 Response, IGA ≥2 Points Improvement Response, and IGA 0 or 1 Response by Visit - MLP Cohort (BOCF)- Entire Treatment Period (FAS)

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Lichen Planopilaris Activity Index (LPPAI)- LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Itch Using Numeric Rating Scale (NRS) by Question - MLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - CLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Patient Assessment of Pain Using Numeric Rating Scale (NRS) by Question -MLP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline for Scalpdex - LPP Cohort (BOCF) (FAS)

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

Summary of Baseline Score and Change From Baseline in Oral Lichen Planus Symptom Severity Measure (OLPSSM) - MLP Cohort - (BOCF) - Entire Treatment Period

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

Summary of Baseline Score and Change From Baseline in Reticular Erythematous Ulcerative Score (REU) - MLP Cohort - (BOCF) - Entire Treatment Period

Average Steps Per Day Assessed by FitBit® / Pedometer

Trough Concentration of Sirolimus

5-D Pruritus Scale Score

Child Dermatological Quality of Life Questionnaire Score

Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale Score

Foot Health Status Questionnaire, Foot Function Domain Score

Foot Health Status Questionnaire, Physical Activity Domain Score

Reviews

Trials

Other Studies